Larimar Therapeutics (LRMR) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Larimar Therapeutics (LRMR) has outperformed Upstream Bio (UPB) over the past year, losing 44.0% versus a loss of 76.0%. Larimar Therapeutics is the larger company by market cap ($280.5 million vs $249.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LRMR | UPB |
|---|---|---|
| Share price | $2.70 | $4.55 |
| Market cap | $280.48M | $249.21M |
| 1-day change | -1.82% | -1.30% |
| YTD return | -29.13% | -83.24% |
| 1-year return | -43.98% | -75.95% |
| 5-year return | -77.72% | — |
| EPS (TTM) | $-1.99 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.42 | $33.68 |
| 52-week low | $2.61 | $4.37 |
| Distance from 52-week high | -57.94% | -86.49% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +433.33% | +584.40% |
| Average volume | 1.31M | 610.08K |
| Shares outstanding | 103.88M | 54.77M |
| Employees | 71 | 75 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LRMR has outperformed UPB by 32.0 percentage points over the past year.
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Healthcare · Biotechnology · 71 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Healthcare · Biotechnology · 75 employees
LRMR vs UPB FAQ
Which is bigger, Larimar Therapeutics or Upstream Bio?
Larimar Therapeutics (LRMR) is larger, with a market capitalization of $280.48M compared with $249.21M for Upstream Bio (UPB).
Which stock has performed better over the past year, LRMR or UPB?
LRMR returned -43.98% over the past 12 months, compared with -75.95% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Larimar Therapeutics and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.